Macro

Global pharmaceutical sales are projected to exceed $2 trillion by 2032, driven by obesity and inflammatory drugs, according to Evaluate's World Preview 2026 report. Eli Lilly's tirzepatide (Mounjaro/Zepbound) is forecast to generate over $70 billion that year, making it the biggest drug ever, while AbbVie's Skyrizi is expected to be the second top-seller at $33 billion. The report highlights a resurgence in M&A, with Chinese assets accounting for over two-thirds of 2026 deal value. However, challenges include U.S. drug pricing pressures, a patent cliff risking $500 billion in sales, and increasing competition in popular indications.

Artificial intelligence is transforming drug discovery by cutting development timelines from years to weeks, addressing a pipeline where 90% of candidates fail. Peptide-based medicines, built from amino acids, are especially suited for AI-driven optimization, enabling rapid analysis of molecular combinations. Eli Lilly's tirzepatide franchise generated $36.5 billion in 2025 revenue (up 215%), and Novo Nordisk's GLP-1 portfolio reached $34.6 billion. Schrodinger's simulation software, used by 18 of the top 20 pharma companies, posted 12% revenue growth in Q1 2026. AI is also overcoming manufacturing and delivery challenges, positioning peptide drugs as a major biotech growth opportunity.

Eli Lilly and Novo Nordisk are leading the S&P 500 healthcare sector, with a focus on metabolic conditions such as diabetes and obesity. A key development is the emergence of oral obesity therapies, which offer a pill-based alternative to traditional injections, potentially expanding patient access. Both companies' large-scale operations and market capitalizations make them major constituents of the index.

IDEXX Laboratories (IDXX) has underperformed the Nasdaq Composite, with shares down 17.1% year-to-date versus NASX's 11.6% gain, due to softening demand in the companion animal market and FX headwinds. Despite outperforming rival Zoetis (ZTS), the stock trades below key moving averages, reflecting investor caution. Analysts maintain a 'Moderate Buy' consensus, citing a 30.4% upside potential.

President Trump announced via social media a plan to impose 100% tariffs on imported generic drugs starting in August 2028, escalating to 200% after one year, to force manufacturers to move production to the U.S. The proposal targets a nearly $500 billion global industry where generics account for 90% of U.S. prescriptions; India supplies over 50% of these drugs, and China provides most active pharmaceutical ingredients. Industry experts and representatives expressed skepticism, noting generic manufacturers operate on single-digit margins, making the tariffs effectively a "market-exit notice." Building domestic manufacturing takes at least four to five years, according to India's Pharmexcil chairman, suggesting the two-year tariff-free period may be insufficient. The Association for Accessible Medicines called for broader policy changes. Companies with existing U.S. production, like Amphastar and Hikma, are better positioned, while Teva and Viatris face greater exposure. It remains unclear if tariffs apply to finished drugs only or also to those using imported ingredients. New reporting highlights that generic drugmakers, unlike patented pharma giants like Johnson & Johnson and Eli Lilly, operate on thin margins due to price wars—prices can fall 70% in two years after patent expiry—making reshoring less viable. Erez Israeli, CEO of Dr. Reddy's, stated tariffs would force price increases in the U.S., and the Global Trade Research Initiative noted many Indian generics would remain cost-competitive even after 100% tariffs, with costs likely passed to patients, insurers, and providers.

Eli Lilly reported Q1 2026 revenue of $19.80 billion, up 55.5% year-over-year, beating consensus estimates, and raised full-year guidance by $2 billion. The FDA cleared Foundayo, the first any-time-of-day oral GLP-1 drug, which drove 80% new-to-class prescriptions in early launch data. Mounjaro revenue surged 125% to $8.66 billion, and Zepbound rose 80% to $4.16 billion. The company also completed a $6.3 billion Centessa acquisition and a $6.5 billion manufacturing plant investment. However, realized prices fell 13% amid volume gains, and Novo Nordisk filed a false-advertising lawsuit. 24/7 Wall St. set a $1,365.51 price target with a buy rating, citing Foundayo's potential to expand the oral obesity market globally.

Indian stock markets suffered their steepest fall in 10 sessions on Wednesday, extending losses to a third consecutive day. The BSE Sensex dropped 715.06 points (0.92%) to 76,755.05, while the Nifty50 fell 191.45 points (0.79%) to 23,996.25, erasing approximately Rs 4.2-4.25 lakh crore in investor wealth. The selloff was driven by escalating US-Iran tensions—with the 11th consecutive night of US strikes targeting Iranian military infrastructure—and a sharp spike in crude oil prices, with Brent surging 3.5% to $94.20 per barrel and WTI climbing 3.8% to $87.56, raising concerns about supply disruptions through the Strait of Hormuz. Additional pressure came from US President Donald Trump's phased tariff plan on imported generic medicines, proposing zero tariffs for two years starting August 1, 2026, followed by 100% for one year and then 200%, hitting India's dominant pharma export sector. The Indian rupee weakened to 96.36 per dollar, while US Treasury yields rose. Broad-based selling hit banking, IT, auto, and pharma stocks, with foreign institutional investors likely net sellers. Analysts expect near-term volatility to persist, hinging on global crude prices and geopolitical developments.

Eli Lilly shares have surged 13.4% this year and 58% over 52 weeks, while Novo Nordisk has fallen 5% over the same period and 62% since July 2024, driven by diverging fortunes in the GLP-1 drug market. The global obesity drug market reached $66 billion in 2025 and is projected to hit $120 billion by 2030. Lilly now holds a 60% share of prescription obesity revenue, largely due to its Zepbound drug, while the two companies collectively control 87% of the market. Novo Nordisk has introduced Wegovy in pill form this spring, boosting its forecasts, but its shares remain under pressure.

The S&P 500 has stalled since its early June record high, as AI-driven megacap tech stocks lose momentum and investors rotate into other sectors. The Magnificent Seven ETF has fallen over 8% from its June peak, and the Philadelphia Semiconductor Index has dropped more than 19%. Despite this, nearly two-thirds of S&P 500 companies have gained since June, with healthcare and financial stocks rising 14% and 12% respectively. The equal-weight S&P 500 has outperformed the market-cap-weighted index, rising nearly 4% since June 2 versus a 2.4% decline in the standard index, and mid- and small-cap stocks have advanced, with the equal-weight S&P 500 up over 13% in 2026. Investors now await Magnificent Seven earnings to assess AI spending returns and high valuations, as rising capital commitments from Microsoft, Amazon, Meta, and Alphabet raise concerns about adequate returns. The rotation signals a broadening but still tech-dependent market, as the Magnificent Seven account for about one-third of the S&P 500's weighting, and a sharp reversal in the AI trade remains a key risk.

The July Personal Consumption Expenditures (PCE) price index rose 3.7% year over year, topping economists' 3.6% estimate and remaining well above the Federal Reserve's 2% target, while core PCE held at 3.3% and monthly headline and core PCE both increased 0.2%. This hot inflation reading pushed Treasury yields higher and dampened rate-cut hopes, prompting investors to rotate into defensive ETFs. Funds like the Consumer Staples Select Sector SPDR ETF (XLP), Health Care Select Sector SPDR ETF (XLV), Utilities Select Sector SPDR ETF (XLU), Vanguard Health Care ETF (VHT), and Invesco S&P 500 Low Volatility ETF (SPLV) offer exposure to less cyclical sectors such as staples, healthcare, and utilities, or lower-volatility stocks, providing a steadier path amid persistent inflation and rising rates. XLP's top holdings include Walmart, Costco, and Procter & Gamble, while XLU's capital-intensive nature keeps it sensitive to interest rates, with State Street holding a neutral view on utilities. SPLV selects the 100 least volatile S&P 500 stocks to reduce portfolio volatility.

The Federal Reserve may raise interest rates in October, with CME Group's FedWatch tool showing a 57.7% probability of a hike at the late-October FOMC meeting, following a 44.1% chance in September. Despite the potential for rising rates to hurt many stocks, three are recommended as buys: UnitedHealth Group, which has seen a 20% year-to-date gain and a 54% earnings jump in Q2 2026; JPMorgan Chase, which benefits from higher net interest income, reporting $25.6 billion in Q2; and Chevron, which gains from elevated fuel prices tied to the Iran war and resurging inflation, with shares up over 20% in 2026.

Baron Health Care Fund's Q2 2026 investor letter highlighted Eli Lilly as a top performer in the obesity drug market, which it projects could exceed $150 billion. Eli Lilly's GLP-1 therapies, including the new daily oral Foundayo, gained coverage from all three major pharmacy benefit managers, reversing prior concerns about a price war with Novo Nordisk. Phase 3 data for retatrutide showed weight loss in the high-20% range at higher doses, while eloralintide demonstrated Zepbound-like efficacy. Eli Lilly closed at $1,121.36 per share on August 3, 2026, with a market cap of $1.06 trillion, up 46.40% over 52 weeks.

Eli Lilly and Novo Nordisk reported starkly contrasting Q2 2026 results in the weight-loss drug market. Lilly posted 48% revenue growth, driven by $14.9 billion in combined Mounjaro and Zepbound sales, capturing roughly 60% of U.S. obesity prescriptions and raising full-year guidance to $85–$87 billion. Novo Nordisk saw adjusted sales rise 7% but gross margins fall to 78.2%, took a DKK 6.3 billion impairment, cut nearly 12,000 jobs, and announced a 50% list price cut for Wegovy effective January 2027. Lilly’s retatrutide met Phase 3 endpoints with weight loss approaching bariatric surgery levels, targeting a U.S. BLA submission in Q1 2027, while Novo’s Wegovy pill reached over 5 million prescriptions, capturing 90% of the oral obesity market. Lilly’s stock rose 77.98% over one year, while Novo trades at an 11 PE with a 3.84% dividend yield.

On August 19, 2026, Moderna and Merck announced that their personalized mRNA cancer vaccine, intismeran (mRNA-4157), combined with Keytruda, succeeded in the Phase 3 INTerpath-001 trial for high-risk adjuvant melanoma, marking the first positive late-stage result for an mRNA cancer therapy and a potential first approved medicine whose genetic instructions are determined by a computer algorithm. The double-blind, placebo-controlled study enrolled over 1,100 patients (1,137 total) with stage IIB–IV melanoma whose tumors were surgically removed, randomized 2-1 to receive the combination or Keytruda alone for about a year. An interim analysis showed the combination significantly extended recurrence-free survival and distant metastasis-free survival, meeting both primary and key secondary endpoints, with the data strong enough to stop the trial early. The five-year Phase 2b data, presented at ASCO 2026, had already shown a 49% reduction in recurrence or death risk and a 59% reduction in distant metastasis or death risk compared to Keytruda alone. The results are considered a landmark: Dr. Julie Gralow, chief medical officer of ASCO, described them as a monumental step forward in validating mRNA technology as a cancer treatment, while Moderna CEO Stéphane Bancel told CNN the results were comparable in significance to the company's November 2020 COVID-19 vaccine data, calling it a new chapter in cancer care. The news sent Moderna shares up 177% to close at $174.38, adding about $45 billion to its market value, while Merck shares rose 12% to a record high of $152.20. The health-care sector rallied, with the Health Care index rising more than 4% in the five trading days leading up to August 21. BioNTech jumped 20.3% to $111.55, and Eli Lilly rose 4.5%, pushing its market cap above $1.2 trillion, the first pharmaceutical company to cross that level. The Nasdaq Biotechnology Index climbed 4.4% to a record closing high. Short sellers faced paper losses of roughly $4.8 billion, as Moderna is one of the most shorted large-cap stocks with short interest at 13.5%. The results surprised even insiders: at a March 2023 leadership meeting, Bancel asked executives who expected the treatment to succeed to stand; none did, including Bancel and President Stephen Hoge, who later told STAT, 'None of us believed it.' RBC Capital Markets analysts wrote that the readout was 'surprisingly positive as we were expecting a year-end readout,' adding that 'the strength of the underlying data must have been compelling to trigger significance at the interim analysis, meaningfully exceeding investor expectations.' The companies have not yet published findings in a peer-reviewed setting but plan to present full data at an upcoming medical conference, possibly ESMO in Madrid from October 23-27, and share results with regulators. Overall survival data are pending and will be evaluated as the study continues. Dr. Ezekiel Emanuel called the results 'a home run, maybe even a grand slam,' while eToro analyst Lale Akoner advised measured expectations, noting manufacturing personalized vaccines at scale could be expensive and complex. The vaccine targets up to 34 unique cancer mutations per patient, built from the tumor's mutational fingerprint. Jefferies’ Tycho Peterson called the update an important proof point for mRNA modality beyond COVID. Bank of America’s Alec Stranahan viewed it as a watershed moment, allowing Moderna to diversify away from infectious disease. Citigroup’s Geoff Meacham noted meeting DMFS with no new safety signals is encouraging but said validation depends on full data and evidence across tumor types. JPMorgan’s Jessica Fye saw the launch as key to profitability but noted success in adjuvant melanoma was already priced in at an 85% probability of success, with read-across to other indications critical for further value. RBC’s Trung Huynh estimated the treatment could be worth up to $2.5 billion and expected a significant 'halo effect' across the robust cancer program. Merck generated $31.68 billion from Keytruda and Keytruda Qlex in 2025, nearly half of the company's sales, and the combination could help extend the franchise beyond Keytruda's primary compound patent expiration in December 2028, though biosimilars have already entered some smaller international markets. William Blair analysts wrote that positive results from INTerpath-001 add positive read-through for ongoing studies of intismeran in other cancer types, specifically flagging a potentially registrational Phase 2 study in adjuvant renal cell carcinoma with data expected by year-end. The companies are also studying intismeran combinations in non-small cell lung, bladder, pancreatic, and stomach cancers. The future of mRNA research faces uncertainty under the Trump administration, with Health Secretary Robert F. Kennedy Jr. criticizing the technology and cutting $500 million in contracts last year. The combined therapy has a huge addressable market: by year-end, the US is expected to register 112,000 new melanoma cases with 8,500 deaths, and globally 330,000 cases were diagnosed in 2022. Hedge funds were bullish on Moderna even before the results, with increased institutional positions and committed capital. An estimated 2.1 million new cancer cases will be diagnosed in the United States this year and an estimated 626,000 will die, according to the American Cancer Society. Personalized cancer vaccines based on the same mRNA technology that brought COVID-19 vaccines to market in record time are showing promising results against certain cancers, despite conflicting signals from U.S. officials about mRNA's technology, safety and potential. 'Personalized cancer vaccines are individualized therapies that train a patient's immune system to recognize and kill cancer cells,' said Dr. Ryan Sullivan, Director of Cutaneous Medical Oncology at Mass General Brigham Cancer Institute. 'These are very promising results that give hope to patients with melanoma and to the entire field of cancer vaccination.' Researchers have been developing vaccines for melanoma, lung, breast, pancreatic, prostate, brain and other cancers. The vaccines are designed to help the immune system recognize tumor-specific markers and attack cancer cells while sparing healthy tissue. One study has kept melanoma at bay for five years. Despite a $500 million reduction in federal support for mRNA technology last year, researchers are reporting encouraging results from personalized cancer vaccines that may reduce the risk of cancer returning by 50%. There have been three notable mRNA cancer vaccine studies and clinical trials: melanoma (skin cancer), which showed a reduced risk of cancer recurrence and spread; pancreatic cancer, which generated cancer-fighting T cells linked to extended remission; and brain cancer, which showed early signs of activating immune defenses against aggressive tumors. Researchers have conducted more than 120 clinical trials of mRNA cancer vaccines since the early 2000s, investigating their potential against numerous cancer types. Cancer vaccine research is advancing rapidly, according to the American Cancer Society. Scientists are developing better methods to identify tumor targets, including those based on mRNA technology, that can help the immune system more effectively recognize and destroy cancer cells. Researchers are also exploring combinations of cancer vaccines and other treatments, such as checkpoint inhibitor immunotherapy, to strengthen the body's anti-cancer response. According to the Cancer Research Institute, 'As exciting as these findings are, there is still much to learn.' Developing and bringing an mRNA cancer vaccine to the public can take 10 to 15 years.

China has unveiled a 2030 plan to become a global leader in biomedical innovation, targeting 25% of the world's first-in-class drugs and 3.5 trillion yuan ($520bn) in annual industry revenue. The initiative, announced via a joint ministerial notice, outlines 25 priority tasks including ramping up R&D, using AI and quantum computing in drug discovery, and building pharma ecosystems. It aims for 50 companies with over $1.5bn in annual revenue and at least five Chinese drugs achieving $1bn in global sales. Emphasis is on next-generation therapies like ADCs, cell and gene therapies, and mRNA vaccines, alongside modernizing traditional Chinese medicine. Citi analysts described the plan as a shift from scale-driven to innovation-driven growth.

Novo Nordisk announced positive phase III results for CagriSema, its once-weekly combination of cagrilintide and semaglutide. In the REIMAGINE 5 study of adults with type 2 diabetes, CagriSema 1.0 mg/1.0 mg achieved superior weight loss (12.4% average reduction) compared to Eli Lilly's tirzepatide 5 mg (9.1%) at week 60, while showing non-inferior HbA1c reduction (1.71% vs. 1.67%). The REDEFINE 9 study evaluated CagriSema with diet and exercise in overweight or obese adults against placebo. CagriSema was well tolerated with a consistent safety profile. These findings bolster Novo's next-generation obesity and diabetes portfolio in the competitive incretin market.

The weight-loss drug market, projected to reach $100 billion in annual sales within a decade, is intensifying as biotech firms race to challenge leaders Novo Nordisk and Eli Lilly. Novo gained an edge with UK and European approval of its Wegovy pill in mid-2024, while Lilly's oral drug orforglipron won US approval in April. Novo is developing successors like amycretin, which showed 14.5% weight loss in a mid-stage trial, and CagriSema, which delivered 22.7% weight loss in one late-stage trial but missed its 25% target. Pfizer entered the race via a 2023 buyout, gaining access to a once-monthly GLP-1 injection.

The global GLP-1 drug market, valued at $58.4 billion in 2025, is projected to reach $66.46 billion in 2026, driven by expanding uses beyond diabetes to weight management and cardiovascular risk reduction. North America holds 57% of the market, with Asia-Pacific growing fastest. Key drugs include Novo Nordisk's Ozempic and Wegovy (semaglutide) and Eli Lilly's Mounjaro (tirzepatide). Oral formulations, such as FDA-approved oral Wegovy in December 2025, are broadening access. Monthly list prices in the U.S. range from $968.52 for Ozempic to $1,349.02 for Wegovy, with high costs remaining a barrier.

UnitedHealth Group faces margin pressure from AI-driven provider coding intensity and arbitration abuse under the No Surprises Act. A Blue Cross Blue Shield Association study found that providers using AI tools added $942 million in costs from 2023 to 2025 by finding more billable secondary diagnoses without corresponding treatment increases. UnitedHealth's commercial cost trend ran above 11% in the first half of 2026, with arbitration alone costing roughly one percentage point of margin. CFO Wayne DeVeydt pushed commercial margin recovery past 2027, a year later than planned. Meanwhile, Optum Insight's operating margin swung from a Q4 2025 loss to a record 25.4% in Q2 2026, though competition from AI-native payment integrity vendors threatens this segment. UNH shares fell 4.5% from September 9 to 23 amid the BCBSA study and Medicare Advantage uncertainty.